|
| Press Releases |
|
 |
|
| Saturday, August 2, 2025 |
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies |
| Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash. more info >> |
|
| Friday, July 25, 2025 |
|
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million |
| Everest Medicines (HKEX 1952.HK, Everest or the " Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the "Sellers"), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue. more info >> |
|
| Friday, July 4, 2025 |
|
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation |
| Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. more info >> |
|
| Thursday, June 12, 2025 |
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances |
| At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON(budesonide delayed release capsules), the world's first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN), and EVER001, a next-generation covalent reversible BTK inhibitor. more info >> |
|
| Monday, June 9, 2025 |
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 |
| At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN). more info >> |
|
| Wednesday, May 7, 2025 |
|
|
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China |
| Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). more info >> |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
| Friday, March 7, 2025 |
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation |
| Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company's total market capitalization to HK$19.791 billion. more info >> |
|
| Wednesday, February 19, 2025 |
|
|
Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32 on Stronger Commercial and R&D Outlook |
| Goldman Sachs' latest report on China's biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon(R), which was recently included in China's National Reimbursement Drug List (NRDL). more info >> |
|
| Thursday, January 2, 2025 |
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, Everest , or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List ('NRDL') on January 1, 2025, NEFECON will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Davos Highlights Physical AI as Key Trend, 51 WORLD (6651.HK) Emerges as Industry Implementer
Jan 22, 2026 20:13 HKT/SGT
|
|
|
Open World Launches Saudi Arabia's First RWA Tokenization Center of Excellence to Advance Vision 2030 Digital Economy Goals
Jan 22, 2026 20:00 HKT/SGT
|
|
|
The 35th Education & Careers Expo opens today
Jan 22, 2026 18:00 HKT/SGT
|
|
|
Fujitsu and Mizuho Bank partner to develop new order and payment processing service for SMEs
Jan 22, 2026 11:30 JST
|
|
|
AmplifiX Releases Comprehensive Sector Report on the Rapid Acceleration of Real-World Asset (RWA) Tokenization
Jan 21, 2026 23:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES to Exhibit Advanced Precious Metal Materials for Medical Device Components at MD&M West 2026
Jan 21, 2026 22:00 JST
|
|
|
Honda to Discontinue Production of Fuel Cell Systems at Fuel Cell System Manufacturing LLC in the U.S.
Jan 21, 2026 17:44 JST
|
|
|
Notice regarding the dissolution of the joint venture in the home elevator business
Jan 21, 2026 17:04 JST
|
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Jan 21, 2026 16:44 JST
|
|
|
MHI and ITB Deepen Research Collaboration on Ammonia-Based Clean Power in Indonesia
Jan 21, 2026 16:37 JST
|
|
|
Asian Financial Forum opens next Monday with a fresh perspective and new tagline, Finance Empowering Business
Jan 21, 2026 14:30 JST
|
|
|
Exito Drives India's Digital-First Revolution with the Flagship 43rd Digital Transformation Summit - India 2026
Jan 21, 2026 13:00 HKT/SGT
|
|
|
MHI-TC Delivers Self-Propelled Mobile Seaport Passenger Boarding Bridge to Yokohama City, Entering Service on January 13th
Jan 21, 2026 11:02 JST
|
|
|
Dowway Proposes Rebranding with a New Name 'Defeng Solife'
Jan 21, 2026 09:51 HKT/SGT
|
|
|
From Computing Chips to Physical AI: Nobel Laureate Hassabis' Trillion-Dollar Paradigm Forecast and 51WORLD's (6651.HK) Industry Breakthrough
Jan 21, 2026 10:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
